Antitumor activity and immune-related gene expression changes following recombinant Mycobacterium smegmatis treatment in a mouse model of bladder cancer
Bladder cancer requires additional therapeutic strategies because of frequent recurrence and progression risk. We evaluated recombinant Mycobacterium smegmatis expressing a human macrophage migration inhibitory factor–interleukin-7 fusion protein (rSmeg-hMIF-hIL-7) in a syngeneic subcutaneous MBT-2 bladder cancer model. Among mice that developed measurable tumors, intraperitoneally treated mice showed reduced tumor growth and longer endpoint-free survival, defined as time to death or humane-endpoint euthanasia. RNA sequencing of four control and three treated tumors identified 116 differentially expressed genes at a fold-change magnitude ≥ 2 and false discovery rate (FDR) < 0.05. Enrichment analyses highlighted immune-related transcriptional differences, although tissue-collection timing and tumor burden limited their attribution to treatment. Cross-species expression comparison identified five exploratory candidates: CCL15, CCRL2, ST3GAL5, SIGLEC6, and TMEM255A. Four showed FDR-significant survival associations in exploratory unadjusted Cox analyses within the same TCGA-BLCA cohort. Expression patterns concordant with those in treated mouse tumors were also associated with papillary histology. RT-qPCR using the same biological samples supported increased Ccl6 and St3gal5 expression after multiple-testing correction. These findings support the antitumor potential of rSmeg-hMIF-hIL-7 and provide exploratory links between murine tumor transcriptional differences and human bladder cancer characteristics.
Authors
- Baek Gil Kim (ORCID: https://orcid.org/0000-0001-6270-1433)
- Dongwook Song
- Young Deuk Choi (ORCID: https://orcid.org/0000-0002-8545-5797)
- Jae Won Park (ORCID: https://orcid.org/0000-0001-5962-9645)
- Hyunho Han
- Gisub Choi
Institutions
- Yonsei University (KR)
- National Health Insurance Service Ilsan Hospital (KR)
- National Health Insurance Service (KR)
- Yonsei University Health System (KR)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1038/s41598-026-80452-x
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Seoul National University
- Yonsei University
- Yonsei University College of Medicine